News
Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...
Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for ...
Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...
Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...
Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, ...
The drug works by acting on key areas of the brain involved in appetite regulation and food intake thereby reducing hunger, ...
Novo Nordisk is seen as having fallen behind in the race for new obesity drugs. It argues it is playing the long game.
Novo Nordisk shares tumble 5.6% after ending Hims & Hers partnership and releasing disappointing CagriSema obesity drug trial ...
Novo Nordisk has launched its weight-loss drug Wegovy in India, while Eli Lilly's Mounjaro has received regulatory approval, ...
Ahead of the launch, the firm has taken steps to amplify its production capacities to ensure adequate supply, and believes ...
Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...
Beyond the Scale” focuses on obesity as a chronic disease — urging empathy, early intervention, and evidence-based care.SINGAPORE - Media OutReach Newswire - 27 June 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results